.jpg "Real estate market in the south of Hai Duong city is bustling")
.jpg "Extremely dangerous forest fire risk in Kinh Mon, Chi Linh")
-ac017d3d3ce25d3405471795d6bb26f0.jpg "Gia Loc needs over 10 billion VND to invest in renovating and expanding landfills.")
Submit a comment
CIMAvax-EGF is the world's first immunotherapy vaccine specifically for lung cancer patients to prevent disease recurrence.
New results recorded in the treatment of lung cancer patients in the Cuban province of Sancti Spíritus have marked another step forward for the medical sector in this Caribbean island nation.
After a period of treatment for late-stage non-small cell lung cancer with the CIMAvax-EGF vaccine, lung cancer patients at Sancti Spíritus achieved a survival rate of more than 85% and improved quality of life.
Since 2010, more than 310 cases diagnosed with non-small cell lung cancer have been vaccinated free of charge at the primary care facility and the Chemotherapy Department of Camilo Cienfuegos Hospital.
One of the longest-living lung cancer patients in Sancti Spíritus is Carmen Vargas. She was prescribed the CIMAvax-EGF vaccine in 2018 and has been treated for nearly seven years with it. At 63, Carmen Vargas, an engineer, still works for the local Agricultural Project.
CIMAvax-EGF, developed by Cuba's Molecular Immunology Center, is the world's first immunotherapy vaccine specifically designed for lung cancer patients to prevent the disease from recurring. To receive the vaccine, patients must first complete chemotherapy and radiotherapy.
CIMAvax-EGF does not have a preventive function but has the ability to inhibit the growth of tumors already present in the patient's body.
According to researchers, unlike the mechanism of action of other lung cancer drugs that directly attack cancer cells, CIMAvax-EGF helps the body produce antibodies to prevent cancer and slow the growth of cancer cells, thereby prolonging the patient's life.
Clinical trials have shown that the drug has no side effects, reduces pain in patients and can extend their lives by an average of more than 11 months, and in some cases even longer.
Cuba's CIMAvax-EGF vaccine is also effective in treating brain cancer, nasopharyngeal cancer, stomach cancer, breast cancer and uterine cancer. Cuban scientists continue to study the drug's effectiveness in treating cancer.
The CIMAvax-EGF vaccine has attracted worldwide attention and has been tested in the United States, Japan and several European countries. US regulators have recommended its use in the most severely ill patients.
According to the World Health Organization (WHO), lung cancer is the leading cause of cancer death worldwide, accounting for the highest mortality rate in both men and women.
